Home » Topics » BioWorld Science

BioWorld Science
RSS

Commencement of phase II trials of LiquiVent for adult ARDS

Dec. 31, 1997

Raxar --new once-daily fluoroquinolone-- now available in U.S.

Dec. 31, 1997

Cambridge Antibody Technology: FY 1997 highlights

Dec. 31, 1997

FDA deems Provigil approvable

Dec. 31, 1997

Favorable phase III trial results reported for HER2 monoclonal antibody

Dec. 31, 1997

Banyu searches for potent, orally bioavailable FXa inhibitors

Dec. 31, 1997

FR-208419: a new dual CCK-A and CCK-B/gastrin receptor antagonist

Dec. 31, 1997

Potent and selective AMPA antagonist from Roche

Dec. 31, 1997

Cytogen updates stockholders

Dec. 31, 1997

New orally active antihypertensive compounds prepared at Rotta

Dec. 31, 1997

Popular Stories

Today's news in brief
BioWorld
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
New mechanism of action identified for QC-6352
BioWorld Science
QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...